Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus), covering 2022-03-31 to 2022-03-31. Get the full timeline:
Most recent: Clinical Trial Update: Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma [Phase 1, Phase 2]